Acute Myeloid Leucaemia
Conditions
Brief summary
Event Free Survival (EFS)
Detailed description
Complex complete remission with no measurable residual disease (CR+CRh+CRi MRD-), Overall survival (OS), Relapse-free survival (RFS), Cumulative Relapse Rate (CIR), Proportion of patients experiencing complete remission (CR), Proportion of Remission with partial haematological recovery (CRh) or remission with incomplete hematopoietic regeneration (CRi), Proportion of patients who did not achieve a response (NR), Percentage of patients experiencing early death (ED), Percentage of patients undergoing allogeneic transplantation, EORTC QLQ-C30 score, Proportion of patients experiencing a composite complete remission (cCR)
Interventions
DRUGPlacebo 0mg
DRUGMIDOSTAURIN
DRUGDAUNORUBICIN
DRUGBIODRIBIN
DRUG1 mg/ml
DRUGCYTARABINE
DRUGVenclyxto 100 mg film-coated tablets
DRUGCLADRIBINE
Sponsors
Medical University Of Lodz
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Event Free Survival (EFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Complex complete remission with no measurable residual disease (CR+CRh+CRi MRD-), Overall survival (OS), Relapse-free survival (RFS), Cumulative Relapse Rate (CIR), Proportion of patients experiencing complete remission (CR), Proportion of Remission with partial haematological recovery (CRh) or remission with incomplete hematopoietic regeneration (CRi), Proportion of patients who did not achieve a response (NR), Percentage of patients experiencing early death (ED), Percentage of patients undergoing allogeneic transplantation, EORTC QLQ-C30 score, Proportion of patients experiencing a composite complete remission (cCR) | — |
Countries
Poland
Outcome results
None listed